Suit Over Allegedly Tainted Valsartan Stays in Federal Court

July 17, 2019, 6:16 PM

Aurobindo Pharma USA won its bid to keep a proposed consumer class suit, alleging it sold tainted heart drugs, in federal court.

Aurobindo showed that the suit involves more than 100 plaintiffs and more than $5 million, making jurisdiction under the Class Action Fairness Act proper, the U.S. District Court for the Southern District of California said.

Companies tend to prefer to litigate in federal courts, believing them to be more business-friendly. Plaintiffs often believe state courts will better protect their rights.

Carrie Collins’s suit stems from recalls of valsartan and other widely used drugs that started last summer. Millions ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.